Daglio David Angelo Jr. 4

Accession 0001127602-24-004738

CIK 0001520262other

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 5:07 PM ET

Size

25.5 KB

Accession

0001127602-24-004738

Form 4

Period: 2024-02-10

Director

Transactions

Exercise/Conversion
Ordinary Shares
2024-02-10+4,533→ 24,229 total
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$22.48/sh+523$11,757→ 26,692 total
Exercise: $22.48Exp: 2031-02-10→ Ordinary Shares (523 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$22.48/sh+90$2,023→ 4,639 total
Exercise: $22.48Exp: 2031-02-10→ Ordinary Shares (90 underlying)
Tax Payment
Ordinary Shares
2024-02-10$27.32/sh−1,088$29,724→ 23,141 total
Other
Restricted Stock Unit Award
2023-11-17+88→ 4,533 total
→ Ordinary Shares (88 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$24.24/sh+313$7,587→ 15,990 total
Exercise: $24.24Exp: 2031-06-14→ Ordinary Shares (313 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$30.86/sh+231$7,129→ 11,785 total
Exercise: $30.86Exp: 2032-07-07→ Ordinary Shares (231 underlying)
Other
Non Qualified Stock Option (Right to Buy)
2023-11-17$30.72/sh+254$7,803→ 12,986 total
Exercise: $30.72From: 2024-06-29Exp: 2033-06-29→ Ordinary Shares (254 underlying)
Other
Restricted Stock Unit Award
2023-11-17+119→ 6,104 total
From: 2024-06-29→ Ordinary Shares (119 underlying)
Exercise/Conversion
Restricted Stock Unit Award
2024-02-10−4,533→ 0 total
→ Ordinary Shares (4,533 underlying)

Holdings

Footnotes (7)

[F1]Each restricted stock unit represents a contingent right to receive one ordinary share.
[F2]Shares are held by The David A Daglio Jr Trust U/A 09/21/17 (the "Daglio Trust"), of which the reporting person is both sole trustee and sole beneficiary.
[F3]Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
[F4]These options are fully vested in accordance with their terms.
[F5]This award is fully vested in accordance with its terms.
[F6]Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
[F7]Shares subject to the restricted stock unit award vest in full on 6/29/2024.

Documents

1 file

Alkermes plc.

CIK 0001520262

Entity typeother